Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Cristina Rubín de Célix und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Biological Products, Gastrointestinal Agents, Biological Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Real‐world data on dose escalation/de‐escalation in inflammatory bowel disease (IBD) are scarce.
Aims
To assess the frequency, effectiveness and durability of escalation/de‐escalation of infliximab, adalimumab, golimumab, vedolizumab and ustekinumab in IBD, and to identify factors influencing relapse and drug discontinuation and re‐escalation efficacy.
Methods
We included patients from the ENEIDA registry of GETECCU who were exposed to biologics and analysed escalations/de‐escalations. We assessed the impact of variables on durability, drug discontinuation and relapse after escalation/de‐escalation.
Results
Of 19,720 patients on biologics, 5096 (26%) underwent dose escalation. Frequency of escalation per patient‐year was 5% (infliximab), 7% (adalimumab), 7% (golimumab), 10% (vedolizumab) and 12% (ustekinumab). Clinical remission was recaptured in 32%–49% of patients. Durability of escalation (24 months) ranged from 66% to 88%. Drug discontinuation was associated with previous biologic exposure and disease duration (infliximab), monotherapy (adalimumab) and ulcerative colitis (ustekinumab). There were 669 de‐escalations. The frequency per patient‐year was 6%, 9%, 5%, 6% and 3% for infliximab, adalimumab, golimumab, vedolizumab and ustekinumab. Maintenance of remission after de‐escalation was observed in 75%–100%. Durability of de‐escalation (12 months) was 82%–90%. Factors associated with relapse were biologic exposure (infliximab) and age at de‐escalation (adalimumab). Re‐escalation benefited most patients.
Conclusions
In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De‐escalation is feasible in some patients. Re‐escalation is generally effective after relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
- Department of Gastroenterology, Hospital Clínic i Provincial, Institut D'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and CIBEREHD, Barcelona, Spain.
- Department of Gastroenterology, Hospital Universitario de La Paz, Madrid, Spain.
- Department of Gastroenterology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
- Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain.
- Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
ORCID-Profile: Cristina Rubín de Célix, Francisco Mesonero, Miriam Mañosa, Xavier Calvet, María José Casanova, Iago Rodríguez-Lago, Carlos Taxonera, Ana Gutiérrez, Alfredo J Lucendo
Förderung
- Eli Lilly and Company
Zitieren
APA
Rubín de Célix, C., Ricart, E., Martín-Arranz, M. D., de Francisco, R., García-Alonso, F. J., Mesonero, F., Gomollón, F., de Castro, L., Ramos, L., García-López, S., Arias, L., Mañosa, M., Iglesias, E., Calvet, X., Suria Bolufer, C., Casanova, M. J., Pérez-Calle, J. L., Giordano, A., Sierra-Ausín, M., …, & Argüelles-Arias, F. (2026). Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70312
Vancouver
Rubín de Célix C, Ricart E, Martín-Arranz MD, de Francisco R, García-Alonso FJ, Mesonero F, et al. Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70312
BibTeX
@article{RubndeClix2026,
author = {Rubín de Célix, Cristina and Ricart, Elena and Martín-Arranz, M Dolores and de Francisco, Ruth and García-Alonso, Francisco Javier and Mesonero, Francisco and Gomollón, Fernando and de Castro, Luisa and Ramos, Laura and García-López, Santiago and Arias, Lara and Mañosa, Miriam and Iglesias, Eva and Calvet, Xavier and Suria Bolufer, Carles and Casanova, María José and Pérez-Calle, José Lázaro and Giordano, Antonio and Sierra-Ausín, Mónica and Vera, Isabel and Navarro-Llavat, Mercè and Lorente, Rufo and Piqueras, Marta and Rivero, Montserrat and Guardiola, Jordi and Esteve, María and Fuentes Coronel, Ana and Rodríguez-Lago, Iago and Ponferrada-Díaz, Ángel and Ber, Yolanda and Tardillo, Carlos and Márquez, Lucía and Carpio, Daniel and Taxonera, Carlos and Bermejo, Fernando and Busquets, David and Camps, Blau and Gutiérrez, Ana and García-Sepulcre, Mariana Fe and Barreiro-de Acosta, Manuel and Marín-Jiménez, Ignacio and Huguet, José M and Fernández-Salazar, Luis Ignacio and Jaó, Jordina and Rodríguez-Gutiérrez, Cristina and Martínez-Flores, Carlos and Bujanda, Luis and Lucendo, Alfredo J and Sesé, Eva and Robledo Andrés, Pilar and Ginard, Daniel and Vega, Pablo and Riera, Joan and Pajares, Ramón and Van Domselaar, Manuel and Almela, Pedro and Martínez Pérez, Teresa and Muñoz-Villafranca, Carmen and Varela, Pilar and Argüelles-Arias, Federico},
title = {Frequency and Effectiveness of Dose Escalation and De‐Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW ‐ IBD Study of ENEIDA},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70312}
}
EUVIMED